logo
Researchers find a link between gut bacteria and genes in colitis flare-ups

Researchers find a link between gut bacteria and genes in colitis flare-ups

LOS ANGELES — Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, and why it behaves so differently from patient to patient. Their research is published Friday in the journal Science Immunology.
Ulcerative colitis is a chronic disease that affects more than 1.2 million people in the United States, according to a 2023 study of medical claims data. It falls under the umbrella of inflammatory bowel disease, or IBD — a group of conditions that includes Chron's disease and is marked by unpredictable flare-ups, long-term discomfort, and treatments that often work inconsistently.
'This study demonstrates that it's not just an imbalance of microbes in your gut or genetics that induce intestinal inflammation — but the interaction between the two,' said Hisako Kayama, an associate professor of immunology at Osaka University and co-senior author of the study.
At the center of that inflammatory response is a protein called STING that helps the body recognize the DNA of bacteria and viruses and mount an immune response. Healthy people are able to keep this response under control with the help of a gene called OTUD3, which acts as a biological brake. But in some people, their OTUD3 gene variant leads that brake to fail — causing the immune system to treat harmless bacteria as a threat. Unchecked, the protein can drive chronic inflammation, particularly in the gut, which is home to many different types of 'good' bacteria.
The protein STING is very important in fighting bacterial infections, said co-author Dr. Kiyoshi Takeda, a professor of immunology at Osaka University. 'But the problem is that the overactivation of STING causes inflammation.'
To explore how this interaction plays out, the researchers studied mice bred specially to have a genetic vulnerability to colitis similar to humans. When feces from the ulcerative colitis patients was transferred to the colons of the mice, they developed more severe colitis symptoms than mice with a normal version of the gene. If they didn't have the gene variant or the microbial trigger, the disease didn't develop.
In total, researchers used tissue and gut bacteria from 124 patients — including 65 with ulcerative colitis and 59 with colorectal cancer — plus 12 healthy people as controls.
The culprit was a molecule called cGAMP, which is made by certain gut bacteria. In healthy mice, researchers know that OTUD3 helps break down excess cGAMP so the immune system doesn't overreact. But in mice without a working version of that gene, cGAMP built up, overactivating STING and causing inflammation.
The findings could help explain why some patients respond poorly to current ulcerative colitis treatments, which typically suppress the immune system as a whole. By pinpointing a single inflammatory pathway, the study opens the door to more precise, personalized therapies — especially for patients who carry this specific gene variant.
Still, the researchers caution that any treatment targeting the STING protein directly must be used carefully, since suppressing it too much could leave patients vulnerable to infection. Alternative approaches, such as targeting cGAMP-producing bacteria, could allow STING to keep doing its job in the rest of the body while dialing down inflammation in the colon.
The variant gene that colitis sufferers have is common. According to past genome-wide studies, it appears in about 53% of Europeans, 52% of Americans and 16% of Japanese people. Not everyone with it develops the disease, lending credence to the idea that it's the interaction between genes and microbes that triggers inflammation.
'This study is helpful in demonstrating a specific example — a genetic variant and a microbial signal — that leads to inflammation,' said Dr. Jonathan Jacobs, a gastroenterologist and microbiome researcher at UCLA who was not involved with the study. 'That's exciting,' he said, because it offers a clear mechanism that ties together many of the risk factors scientists have long observed in inflammatory bowel disease.
Even if it turns out not many people are vulnerable to this particular gut-genetic interaction, he said, the research could lead to more personalized treatment. 'It moves us closer to precision medicine,' Jacobs said.
The shift toward more targeted treatment could make a world of difference for patients like Anderson Hopley, a volunteer with the Orange County and Los Angeles chapter of the Crohn's and Colitis Foundation who was diagnosed with Crohn's this year.
'I know people who have medication that'll work for a couple years, maybe even just a couple months, and then it kind of randomly stops,' he said. 'They have to adjust everything.'
Although Hopley has Crohn's, not ulcerative colitis, he said the new study still resonates.
'I think it'd be really nice to know what causes this,' he said. 'Even if there's not a cure yet, just having an answer — some clarity — would be a step in the right direction.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mindfulness Therapy Aids IBD Patients With Mental Distress
Mindfulness Therapy Aids IBD Patients With Mental Distress

Medscape

timea day ago

  • Medscape

Mindfulness Therapy Aids IBD Patients With Mental Distress

TOPLINE: Mindfulness-based cognitive therapy reduced psychological distress and improved well-being of patients with inflammatory bowel disease (IBD), and it may offer benefits for sleep quality and inflammation. METHODOLOGY: Even in remission, many patients with IBD experience anxiety, depression, fatigue, and poor sleep, which can lower their quality of life, undermine self-care, and drive up healthcare use. Researchers conducted this trial in the Netherlands between July 2021 and May 2022 to strengthen the evidence for the effectiveness of mindfulness-based cognitive therapy in reducing psychological distress in patients with IBD who had been in remission for at least 3 months and experienced at least mild levels of distress. They randomly assigned 142 patients (mean age, 48.6 years; 64.1% women) to receive either mindfulness therapy plus usual treatment (n = 70; intervention group) or only usual treatment (n = 72; control group); the follow-up period lasted 12 months. The mindfulness therapy program included eight weekly group sessions of 2.5 hours, 30-45 minutes of daily home practice, and a 6-hour silent retreat day between sessions six and seven. Usual treatment included pharmacologic and surgical disease control treatments and the prevention of complications. The primary outcome was psychological distress post-intervention (3 months from baseline), measured using the Hospital Anxiety and Depression Scale (HADS) total score. Secondary outcomes included well-being, sleep, self-compassion, mindfulness skills, and disease activity. TAKEAWAY: Patients in the intervention group vs the control group showed reduced psychological distress (Cohen d [d], -0.61) and an improvement in the HADS total score (unstandardized coefficient B, -3.4; P < .001) at 3 months from baseline. The HADS total scores remained lower in the intervention group vs the control group during the entire 12-month follow-up duration. Compared with patients in the control group, those in the intervention group showed improved well-being (d, 0.41) and increases in mindfulness skills (d, 0.46) and self-compassion (d, 0.42). Patients in the intervention group vs the control group had a reduced total sleep time (d, -0.67) but an increased proportion of deep sleep (d, 0.7). No between-group difference was observed in the occurrence of disease flares, but patients in the control group showed a significant reduction in fecal calprotectin levels, an indicator of intestinal inflammation compared with patients in the control group (d, -0.49). IN PRACTICE: 'Our results demonstrate that MBCT [mindfulness-based cognitive therapy] could be a valuable addition to the currently limited number of psychological treatment options for patients with IBD with psychological distress. The group format of MBCT allows for the simultaneous treatment of more patients, potentially making it more cost-effective than individual therapy. Additionally, group therapy provides opportunities for peer support,' the authors of the study wrote. SOURCE: This study, led by Milou M. ter Avest, MD, Department of Psychiatry, Centre for Mindfulness, Radboud University Medical Centre, Nijmegen, the Netherlands, was published online in Inflammatory Bowel Diseases. LIMITATIONS: This study was limited by its unblinded design, risking expectation bias in self-reports. Mindfulness teachers had varied competence levels, which may have introduced bias. The study did not assess sleep disorders such as obstructive sleep apnea, narcolepsy, or restless legs syndrome that may have affected the sleep metrics. Additionally, electroencephalography headbands were not available for all patients, and technical and self-application issues may have led to unusable nights and data loss. DISCLOSURES: This trial was supported by ZonMw (the Netherlands Organisation for Health Research and Development) and the MindMore Foundation. Two authors reported serving on the advisory boards of various pharmaceutical companies, and one of them also reported receiving a grant from Royal DSM. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Caution Needed in Prescribing IBD Meds in CKD
Caution Needed in Prescribing IBD Meds in CKD

Medscape

timea day ago

  • Medscape

Caution Needed in Prescribing IBD Meds in CKD

TOPLINE: Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional therapies, including immunomodulators and aminosalicylates, as well as with JAK inhibitors. METHODOLOGY: From 4%-23% of patients with IBD also have renal disease, which can affect how the body processes medications; however, little data is available to guide physicians in choosing safe and effective IBD treatments for patients with advanced CKD. Researchers conducted a review of studies about IBD treatments in the setting of CKD by searching MEDLINE and EMBASE through March 31, 2025, using relevant keywords. IBD treatments evaluated were corticosteroids, aminosalicylates, immunomodulators (such as thiopurines and methotrexate), calcineurin inhibitors, biologics (such as monoclonal antibodies against tumor necrosis factors (anti-TNFs), integrin receptors, and interleukins), and small molecules (such as JAK inhibitors and sphingosine-1-phosphate [S1P] receptor modulators). TAKEAWAY: Corticosteroids in advanced kidney disease, including in patients requiring dialysis, do not require dosage adjustment. Budesonide is preferred over prednisolone, and corticosteroids are typically administered at the lowest effective dose for the shortest duration. Mesalazine, an aminosalicylate, can trigger acute interstitial nephritis; the immunomodulator methotrexate, even at 2-4 mg/wk, may cause irreversible renal decline, profound myelosuppression, and higher mortality in patients with end-stage kidney disease on hemodialysis; and calcineurin inhibitors can be nephrotoxic by reducing renal blood flow and glomerular filtration rate. Monoclonal antibodies, including anti-TNF, anti-integrin, and anti-interleukin 12/23 therapies, demonstrated safety in renal insufficiency and hemodialysis. For JAK inhibitors and thiopurines, dose adjustments were recommended in advanced renal disease, whereas S1P receptor modulators could be used in CKD without any dose adjustments. IN PRACTICE: 'Selecting appropriate therapeutics for managing IBD in patients with CKD necessitates a tailored approach, emphasizing diligent surveillance of renal function to optimize treatment efficacy and minimize renal compromise. Dose adjustments of IBD therapeutics are not required for patients with stage I or II CKD. Depending on specific drug metabolism and renal excretion, dose adjustments may be required at more advanced-stage CKD,' the authors wrote. SOURCE: The study, led by Lynna Chen, Eastern Health Clinical School, Monash University in Melbourne, Australia, was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: This review did not discuss limitations. DISCLOSURES: The authors received no specific funding for this work. Two authors disclosed receiving advisory fees and serving as speakers for various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Researchers find a link between gut bacteria and genes in colitis flare-ups
Researchers find a link between gut bacteria and genes in colitis flare-ups

Yahoo

time7 days ago

  • Yahoo

Researchers find a link between gut bacteria and genes in colitis flare-ups

Researchers have identified a gut-genetic interaction that could trigger an overactive immune response in the colon — offering one possible explanation for the pain and bleeding of ulcerative colitis, and why it behaves so differently from patient to patient. Their research is published Friday in the journal Science Immunology. Ulcerative colitis is a chronic disease that affects more than 1.2 million people in the United States, according to a 2023 study of medical claims data. It falls under the umbrella of inflammatory bowel disease, or IBD — a group of conditions that includes Chron's disease and is marked by unpredictable flare-ups, long-term discomfort, and treatments that often work inconsistently. 'This study demonstrates that it's not just an imbalance of microbes in your gut or genetics that induce intestinal inflammation — but the interaction between the two,' said Hisako Kayama, an associate professor of immunology at Osaka University and co-senior author of the study. At the center of that inflammatory response is a protein called STING that helps the body recognize the DNA of bacteria and viruses and mount an immune response. Healthy people are able to keep this response under control with the help of a gene called OTUD3, which acts as a biological brake. But in some people, their OTUD3 gene variant leads that brake to fail — causing the immune system to treat harmless bacteria as a threat. Unchecked, the protein can drive chronic inflammation, particularly in the gut, which is home to many different types of "good" bacteria. The protein STING is very important in fighting bacterial infections, said co-author Dr. Kiyoshi Takeda, a professor of immunology at Osaka University. 'But the problem is that the overactivation of STING causes inflammation.' To explore how this interaction plays out, the researchers studied mice bred specially to have a genetic vulnerability to colitis similar to humans. When feces from the ulcerative colitis patients was transferred to the colons of the mice, they developed more severe colitis symptoms than mice with a normal version of the gene. If they didn't have the gene variant or the microbial trigger, the disease didn't develop. In total, researchers used tissue and gut bacteria from 124 patients — including 65 with ulcerative colitis and 59 with colorectal cancer — plus 12 healthy people as controls. The culprit was a molecule called cGAMP, which is made by certain gut bacteria. In healthy mice, researchers know that OTUD3 helps break down excess cGAMP so the immune system doesn't overreact. But in mice without a working version of that gene, cGAMP built up, overactivating STING and causing inflammation. The findings could help explain why some patients respond poorly to current ulcerative colitis treatments, which typically suppress the immune system as a whole. By pinpointing a single inflammatory pathway, the study opens the door to more precise, personalized therapies — especially for patients who carry this specific gene variant. Still, the researchers caution that any treatment targeting the STING protein directly must be used carefully, since suppressing it too much could leave patients vulnerable to infection. Alternative approaches, such as targeting cGAMP-producing bacteria, could allow STING to keep doing its job in the rest of the body while dialing down inflammation in the colon. The variant gene that colitis sufferers have is common. According to past genome-wide studies, it appears in about 53% of Europeans, 52% of Americans and 16% of Japanese people. Not everyone with it develops the disease, lending credence to the idea that it's the interaction between genes and microbes that triggers inflammation. 'This study is helpful in demonstrating a specific example — a genetic variant and a microbial signal — that leads to inflammation,' said Dr. Jonathan Jacobs, a gastroenterologist and microbiome researcher at UCLA who was not involved with the study. 'That's exciting," he said, because it offers a clear mechanism that ties together many of the risk factors scientists have long observed in inflammatory bowel disease. Even if it turns out not many people are vulnerable to this particular gut-genetic interaction, he said, the research could lead to more personalized treatment. 'It moves us closer to precision medicine,' Jacobs said. The shift toward more targeted treatment could make a world of difference for patients like Anderson Hopley, a volunteer with the Orange County and Los Angeles chapter of the Crohn's and Colitis Foundation who was diagnosed with Crohn's this year. 'I know people who have medication that'll work for a couple years, maybe even just a couple months, and then it kind of randomly stops,' he said. 'They have to adjust everything.' Although Hopley has Crohn's, not ulcerative colitis, he said the new study still resonates. 'I think it'd be really nice to know what causes this,' he said. 'Even if there's not a cure yet, just having an answer — some clarity — would be a step in the right direction.' This story originally appeared in Los Angeles Times. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store